摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[5-(1,1-difluoroethyl)-1,2,4-oxadiazol-3-yl]-N-methylbicyclo[2.2.2]octane-1-carboxamide | 1439792-59-2

中文名称
——
中文别名
——
英文名称
4-[5-(1,1-difluoroethyl)-1,2,4-oxadiazol-3-yl]-N-methylbicyclo[2.2.2]octane-1-carboxamide
英文别名
——
4-[5-(1,1-difluoroethyl)-1,2,4-oxadiazol-3-yl]-N-methylbicyclo[2.2.2]octane-1-carboxamide化学式
CAS
1439792-59-2
化学式
C14H19F2N3O2
mdl
——
分子量
299.321
InChiKey
MYDUZHPJIZPWFJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.79
  • 拓扑面积:
    68
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    C8H3F3I2N44-[5-(1,1-difluoroethyl)-1,2,4-oxadiazol-3-yl]-N-methylbicyclo[2.2.2]octane-1-carboxamide草酰氯 作用下, 以 二氯甲烷N,N-二甲基甲酰胺甲苯 为溶剂, 以21%的产率得到C8H3F3I2O2
    参考文献:
    名称:
    Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension
    摘要:
    In an effort to understand the origin of blood-pressure lowering effects observed in recent clinical trials with 11 beta-HSD1 inhibitors, we examined a set of 11 beta-HSD1 inhibitors in a series of relevant in vitro and in vivo assays. Select 11 beta-HSD1 inhibitors reduced blood pressure in our preclinical models but most or all of the blood pressure lowering may be mediated by a 11 beta-HSD1 independent pathway. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.03.011
  • 作为产物:
    描述:
    4-(甲氧羰基)双环[2.2.2]辛烷-1-羧酸ammonium hydroxideN,N-二异丙基乙胺N,N'-羰基二咪唑 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 、 potassium hydroxide 作用下, 以 甲醇二氯甲烷 为溶剂, 生成 4-[5-(1,1-difluoroethyl)-1,2,4-oxadiazol-3-yl]-N-methylbicyclo[2.2.2]octane-1-carboxamide
    参考文献:
    名称:
    Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension
    摘要:
    In an effort to understand the origin of blood-pressure lowering effects observed in recent clinical trials with 11 beta-HSD1 inhibitors, we examined a set of 11 beta-HSD1 inhibitors in a series of relevant in vitro and in vivo assays. Select 11 beta-HSD1 inhibitors reduced blood pressure in our preclinical models but most or all of the blood pressure lowering may be mediated by a 11 beta-HSD1 independent pathway. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2013.03.011
点击查看最新优质反应信息